{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-030286","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2026-06-26T20:05:40+00:00","discovered_at":"2026-06-26T20:07:01.437497+00:00","generated_at":"2026-06-26T20:08:02.200097+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BriaPro subsidiary reports 9-month net loss of $712K; going concern uncertainty","bullets":["Net loss for 9 months ended April 30, 2026: $712,236, vs $519,804 in prior-year period.","Accumulated deficit of $1,892,661; cash $299,950 vs $1 at July 31, 2025.","Acquired sCD80 license from parent BriaCell for 23,972,589 shares valued at $846,532.","Due to related parties (BriaCell) $2,093,345; going concern depends on parent financing.","R&D expenses $649,991; granted 7,189,000 RSUs to directors on April 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-030286","json":"https://secwatch.observer/filing/0001493152-26-030286.json","markdown":"https://secwatch.observer/filing/0001493152-26-030286.md","text":"https://secwatch.observer/filing/0001493152-26-030286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/0001493152-26-030286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:08:02.200097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}